Design der JUNIPER Studie auf Grundlage der Phase 1 Daten zu Abemaciclib: Eine randomisierte Phase 3 Studie zum Vergleich von Abemaciclib versus Erlotinib bei NSCLC im Stadium IV mit nachgewiesener KRAS mutation

Autor: Edward M. Chan, A Patnaik, AW Tolcher, Lee S. Rosen, C. Kropf-Sanchen, L Wunderle, Jonathan W. Goldman, Geoffrey I. Shapiro, Luis Paz-Ares, Achim Rittmeyer, Martin Reck, G Schmid-Bindert, C Wesseler

Publikováno v: Pneumologie. 71:S1-S125

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::997b2ab61efe325e7e2b2581ab8c7a8f
https://doi.org/10.1055/s-0037-1598328

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.

Autor: Chen CT; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California., Khanna V; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California., Kummar S; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.; Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon., Abdul-Karim RM; NEXT Oncology, San Antonio, Texas., Sommerhalder D; NEXT Oncology, San Antonio, Texas., Tolcher AW; NEXT Oncology, San Antonio, Texas., Ueno NT; University of Texas MD Anderson Cancer Center, Houston, Texas., Davis SL; University of Colorado Cancer Center, Aurora, Colorado., Orr DW; Mary Crowley Cancer Research, Dallas, Texas., Hamilton E; Sarah Cannon Research Institute, Nashville, Tennessee., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida., Spira AI; Virginia Cancer Specialists, Fairfax, Virginia., Jauhari S; Florida Cancer Specialists/Sarah Cannon Research Institute, Lake Mary, Florida., Florou V; 1Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Duff M; ORIC Pharmaceuticals, South San Francisco, California., Xu R; ORIC Pharmaceuticals, South San Francisco, California., Wang J; ORIC Pharmaceuticals, South San Francisco, California., Barkund SR; ORIC Pharmaceuticals, South San Francisco, California., Zhou H; ORIC Pharmaceuticals, South San Francisco, California., Pankov A; ORIC Pharmaceuticals, South San Francisco, California., Kong W; ORIC Pharmaceuticals, South San Francisco, California., Jahchan NS; ORIC Pharmaceuticals, South San Francisco, California., Jackson EL; ORIC Pharmaceuticals, South San Francisco, California., Sun JD; ORIC Pharmaceuticals, South San Francisco, California., Junttila MR; ORIC Pharmaceuticals, South San Francisco, California., Multani PS; ORIC Pharmaceuticals, South San Francisco, California., Daemen A; ORIC Pharmaceuticals, South San Francisco, California., Chow Maneval E; ORIC Pharmaceuticals, South San Francisco, California., Munster PN; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Sep 01; Vol. 4 (9), pp. 2415-2426.

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.

Autor: Bardia A; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Krop IE; Yale Cancer Center, New Haven, CT.; Dana-Farber Cancer Institute, Boston, MA., Kogawa T; Department of Advanced Medical Development, Cancer Institute Hospital of JFCR, Tokyo, Japan., Juric D; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Tolcher AW; South Texas Accelerated Research Therapeutics, San Antonio, TX.; NEXT Oncology, San Antonio, TX.; Texas Oncology, San Antonio, TX., Hamilton EP; Sarah Cannon Research Institute, Nashville, TN.; Tennessee Oncology, PLLC, Nashville, TN., Mukohara T; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Lisberg A; Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA., Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.; Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Hospital, Wakayama, Japan., Spira AI; Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA., Tsurutani J; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan., Damodaran S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Papadopoulos KP; Clinical Research, START, San Antonio, TX., Greenberg J; Global Oncology Clinical Development, Daiichi Sankyo, Inc, Basking Ridge, NJ.; Global Oncology Clinical Development, Daiichi Sankyo Europe GmbH, Munich, Germany., Kobayashi F; Data Intelligence, Daiichi Sankyo, Co, Ltd, Tokyo, Japan., Zebger-Gong H; Global Oncology Clinical Development, Daiichi Sankyo Europe GmbH, Munich, Germany., Wong R; Global Oncology Clinical Development, Daiichi Sankyo, Co, Ltd, Tokyo, Japan., Kawasaki Y; Global Oncology Clinical Development, Daiichi Sankyo, Inc, Basking Ridge, NJ., Nakamura T; Data Intelligence, Daiichi Sankyo, Co, Ltd, Tokyo, Japan., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jul 01; Vol. 42 (19), pp. 2281-2294. Date of Electronic Publication: 2024 Apr 23.

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.

Autor: Rodon J; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston. Electronic address: JRodon@mdanderson.org., Rodriguez E; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami., Maitland ML; Inova Schar Cancer Institute and University of Virginia Comprehensive Cancer Center, Fairfax., Tsai FY; Hematology/Oncology, HonorHealth, Scottsdale., Socinski MA; AdventHealth Cancer Institute, Orlando., Berlin JD; Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville., Thomas JS; Division of Medical Oncology - Head and Neck, University of Southern California Norris Comprehensive Cancer Center, Los Angeles., Al Baghdadi T; Hematology Oncology, IHA Medical Group, Ypsilanti., Wang IM; Pfizer Inc, New York., Guo C; Pfizer Inc, San Diego., Golmakani M; Pfizer Inc, New York., Clark LN; Pfizer Inc, New York., Gazdoiu M; Pfizer Inc, New York., Li M; Pfizer Inc, New York., Tolcher AW; NEXT Oncology, San Antonio, USA.

Publikováno v: ESMO open [ESMO Open] 2024 Apr; Vol. 9 (4), pp. 102961. Date of Electronic Publication: 2024 Apr 18.

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Autor: Stathis A; Oncology Institute of Southern Switzerland, EOC, via A. Gallino 12, Bellinzona 6500, Switzerland. anastasios.stathis@eoc.ch., Tolcher AW; NEXT Oncology, San Antonio, TX, USA., Wang JS; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Renouf DJ; BC Cancer-Vancouver Center, Vancouver, BC, Canada., Chen LC; Merck & Co., Inc., Rahway, NJ, USA., Suttner LH; Merck & Co., Inc., Rahway, NJ, USA., Freshwater T; Merck & Co., Inc., Rahway, NJ, USA., Webber AL; Merck & Co., Inc., Rahway, NJ, USA., Nayak T; Merck & Co., Inc., Rahway, NJ, USA., Siu LL; Princess Margaret Cancer Centre, Toronto, ON, Canada.

Publikováno v: Investigational new drugs [Invest New Drugs] 2023 Jun; Vol. 41 (3), pp. 380-390. Date of Electronic Publication: 2023 Apr 11.